Shopping Cart
- Remove All
- Your shopping cart is currently empty
CSRM617 is a selective small molecule inhibitor of the transcription factor ONECUT2 (OC2, the main regulator of androgen receptor). The Kd in SPR analysis is 7.43 uM, which can directly bind to the OC2-HOX domain. CSRM617 induces apoptosis by cleaving the presence of Caspase-3 and PARP. CSRM617 is well tolerated in a mouse model of prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 1-2 weeks | |
50 mg | $1,980 | 1-2 weeks | |
100 mg | $2,500 | 1-2 weeks |
Description | CSRM617 is a selective small molecule inhibitor of the transcription factor ONECUT2 (OC2, the main regulator of androgen receptor). The Kd in SPR analysis is 7.43 uM, which can directly bind to the OC2-HOX domain. CSRM617 induces apoptosis by cleaving the |
In vitro | CSRM617 (0.01-100 μM; 48 hours) inhibits cell growth in PC-3, 22Rv1, LNCaP, and C4-2 cell lines. At 10-20 μM for 48 hours, it induces 22Rv1 cell apoptosis, leading to concentration-dependent cell death. At 20 μM for 72 hours, it induces apoptosis in 22Rv1 cells by cleaving Caspase-3 and PARP. |
Molecular Weight | 255.23 |
Formula | C10H13N3O5 |
Cas No. | 787504-88-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.